|
|
News Breaks | | | | March 11, 2013 | | 06:10 EDT |  | ZIOP | Ziopharm initiates Phase 2 study of Ad-RTLS IL-12
Ziopharm announced the initiation of a randomized, open label Phase 2 clinical study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer. The two-part, multi-center U.S. study will enroll up to 68 patients with non-resectable, recurrent or metastatic breast cancer who have visible lesions or lesions accessible by injection. The study is designed to assess the safety and efficacy of the drug combination of Ad-RTS IL-12 and palifosfamide. Ad-RTS IL-12 is a targeted and controlled DNA-based therapeutic designed to express interleukin-12 (IL-12), a protein important for an immune response to cancer. | |
|
News For ZIOP From The Last 14 Days Check below for free stories on ZIOP the last two weeks. |
|
|
| May 7, 2013 | | 16:43 EDT |  | ZIOP | Ziopharm reports Q1 EPS (15c), consensus (27c)
Reports Q1 revenue $200K, consensus $160K. | |
|
|
|
|
|
|
